Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433877 | 0.79 | POLB (0.43) | POLBGAAEPHX2CA12CA14 | |
| SCHEMBL8653954 | 0.78 | TSHR (0.55) | GAAEPHX2CA12CA14CA7 | |
| SCHEMBL20460677 | 0.77 | POLB (0.48) | POLBGAAEPHX2CA12CA14 | |
| SCHEMBL7443456 | 0.77 | GAA (0.40) | POLBGAAEPHX2CA7TSHR | |
| SCHEMBL3944331 | 0.77 | TSHR (0.59) | POLBGAAEPHX2CA12CA14 | |
| SCHEMBL334176 | 0.76 | TSHR (0.50) | POLBGAAEPHX2TSHRMAPT | |
| SCHEMBL20210567 | 0.75 | TSHR (0.42) | POLBGAAEPHX2TSHRMAPT | |
| SCHEMBL22544831 | 0.75 | PAOX (0.45) | POLBGAAEPHX2CA12CA14 | |
| SCHEMBL30771776 | 0.74 | POLB (0.41) | POLBGAAEPHX2CA12CA14 | |
| SCHEMBL30529014 | 0.74 | TSHR (0.48) | POLBGAAEPHX2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192894-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | POLB 3771/4885GAA 290/4885EPHX2 2485/4885 |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | POLB 3771/4885GAA 290/4885EPHX2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.